Clearmind Medicine CMND 深 沪
等待开盘 10-07 09:30:00 美东时间
5.84
-0.160
-2.67%
华盛通- 最 高6.1746
- 今 开5.89
- 成交量 3.54万股
- 最 低 5.701
- 昨 收 6.00
- 总市值 1966.37万
- 52周最高 3840.00
- 市盈率 静 --
- 换手率 1.05%
- 52周最低 5.25
- 委 比 88.60%
- 总股本 336.71万
- 历史最高 585600.00
- 量 比 0.32
- 振 幅 7.89%
- 历史最低 5.701
- 每 手 1
- 风险率 899.54%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Clearmind Medicine Announces 1-For-8 Reverse Share Split, Effective October 5, 2026
learmind Medicine Inc. (the "Company") is announcing that it will effect a reverse share split of the Company’s common shares at the ratio of 1-for-8, such that each eight (8) common shares, no par value, shall be consolidated into one (1) common share, no par value. The first date when the Company’...
10-01 04:54
Clearmind Medicine Delivers Briefing to FDA Following Invitation to Historic Psychedelic Hearing in Washington, D.C.
Clearmind Medicine Inc. participated in a historic FDA hearing on psychedelic drugs, with Mary-Elizabeth Gifford discussing patient access and insights from the company’s clinical trials at Yale and Johns Hopkins. Clearmind’s neuroplastogenic compounds, which eliminate hallucinogenic effects while retaining therapeutic benefits, may reduce the need for costly supervised dosing, offering a scalable treatment model. The company’s MEAI candidate, ta...
09-17 11:42
Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial
Clearmind Medicine Inc. announced the enrollment of the first AUD patients in its CMND-100 clinical trial, marking a significant milestone in its neuroplastogen-based treatment development.
09-11 12:00
Clearmind Medicine Inc. GAAP EPS of -$0.57
Clearmind Medicine Inc. press release (CMND): Q3 GAAP EPS of -$0.57. More on Clearmind Medicine Inc. Clearmind Medicine signs agreement to acquire 51% stake in Charging Robotics Financial information ...
09-11 04:19
Clearmind Medicine Stock Slides Friday: What's Happening?
Shares of Clearmind Medicine Inc. (NASDAQ:CMND) are trading lower Friday morning as investors digest news of the clinical-stage biotech company expanding beyond its core pharmaceutical focus to acquire a majority stake in an electric vehicle charging firm. Clearmind Medicine shares are sliding. What...
09-04 20:59
Clearmind Medicine signs agreement to acquire 51% stake in Charging Robotics
Clearmind Medicine (CMND) on Friday said it has entered into a definitive agreement to acquire a 51% stake in Charging Robotics, an EV wireless charging firm for automated parking and robotaxis. Under...
09-04 19:39
Clearmind Medicine Initiates Phase lla, Double-Blind, Placebo-Controlled Phase I/IIa Clinical Trial Evaluating CMND-100 For Treatment Of AUD
Clearmind Medicine Inc. (NASDAQ:CMND) (the “Company”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogen for scalable treatment of neuropsychiatric, metabolic, and addiction disorders including Alcohol Use Disorder (“AUD”), announced today th...
09-01 19:38
Clearmind Medicine Advances Its IP Portfolio With Publication In U.S. Of Its Patent Application For Novel Combination Of 3,4-Methylenedioxymethamphetamine And N-Acylethanolamines To Treat Post-Traumatic Stress Disorder
Clearmind Medicine Inc. (NASDAQ:CMND), a clinical-stage biopharmaceutical company advancing non-hallucinogenic, psychedelic-derived neuroplastogens for scalable treatment of neuropsychiatric, metabolic, and addiction disorders, including AUD, today announced an advancement of its IP portfolio...
08-24 20:07
Clearmind Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation
Clearmind Medicine Inc. announced the publication of a U.S. patent application covering a novel combination of MDMA and N-acylethanolamines, such as PEA, for treating PTSD, anxiety, and eating disorders. This milestone stems from its collaboration with NeuroThera Labs Inc., contributing to a growing intellectual property portfolio with 13 patent applications. The new application highlights PEA's potential to enhance MDMA's therapeutic effects, re...
08-24 12:03
Clearmind Medicine Completes Treatment For All Participants In Part A Of Its Ongoing Phase I/II Clinical Trial Evaluating CMND-100 For Alcohol Use Disorder
All 24 participants across cohorts 1 through 4 have successfully completed treatment according to the study protocol. The Company is currently assessing the dataset and, assuming results remain favorable, intends to initiate the next stage of the clinical program in AUD patients. "We are pleased to ...
07-28 19:49
